BIOTON S.A. (BIO.WA)
PLN 2.98
(-0.83%)
PLN 2.98
(-0.83%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 64.81 Million PLN | -3.35% |
| 2022 | 67.05 Million PLN | -33.75% |
| 2021 | 101.21 Million PLN | 15.2% |
| 2020 | 87.86 Million PLN | -26.93% |
| 2019 | 120.25 Million PLN | 15.79% |
| 2018 | 103.85 Million PLN | -34.91% |
| 2017 | 159.53 Million PLN | 13.42% |
| 2016 | 140.65 Million PLN | -27.4% |
| 2015 | 193.73 Million PLN | 16.14% |
| 2014 | 166.81 Million PLN | -15.98% |
| 2013 | 198.53 Million PLN | 7.61% |
| 2012 | 184.5 Million PLN | -22.88% |
| 2011 | 239.22 Million PLN | 94.18% |
| 2010 | 123.19 Million PLN | -37.52% |
| 2009 | 197.18 Million PLN | -54.25% |
| 2008 | 430.99 Million PLN | 18.78% |
| 2007 | 362.84 Million PLN | 7649.88% |
| 2006 | -4.8 Million PLN | -115.56% |
| 2005 | 30.88 Million PLN | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q2 | 52.73 Million PLN | -11.15% |
| 2024 Q1 | 59.35 Million PLN | -8.41% |
| 2023 FY | 64.81 Million PLN | -3.35% |
| 2023 Q1 | 70.76 Million PLN | 5.53% |
| 2023 Q3 | 72.27 Million PLN | -4.46% |
| 2023 Q2 | 75.65 Million PLN | 6.91% |
| 2023 Q4 | 64.81 Million PLN | -10.33% |
| 2022 Q2 | 82.92 Million PLN | -4.13% |
| 2022 Q1 | 86.49 Million PLN | -14.54% |
| 2022 FY | 67.05 Million PLN | -33.75% |
| 2022 Q4 | 67.05 Million PLN | -3.83% |
| 2022 Q3 | 69.72 Million PLN | -15.92% |
| 2021 FY | 101.21 Million PLN | 15.2% |
| 2021 Q2 | 107.22 Million PLN | 13.09% |
| 2021 Q1 | 94.81 Million PLN | 7.91% |
| 2021 Q3 | 107.41 Million PLN | 0.18% |
| 2021 Q4 | 101.21 Million PLN | -5.77% |
| 2020 FY | 87.86 Million PLN | -26.93% |
| 2020 Q2 | 101.41 Million PLN | -16.85% |
| 2020 Q3 | 100.52 Million PLN | -0.88% |
| 2020 Q4 | 87.86 Million PLN | -12.6% |
| 2020 Q1 | 121.96 Million PLN | 1.43% |
| 2019 FY | 120.25 Million PLN | 15.79% |
| 2019 Q1 | 130.31 Million PLN | 25.48% |
| 2019 Q2 | 139.05 Million PLN | 6.7% |
| 2019 Q3 | 126.76 Million PLN | -8.84% |
| 2019 Q4 | 120.25 Million PLN | -5.14% |
| 2018 FY | 103.85 Million PLN | -34.91% |
| 2018 Q4 | 103.85 Million PLN | -12.39% |
| 2018 Q1 | 153.1 Million PLN | -4.03% |
| 2018 Q2 | 178.12 Million PLN | 16.34% |
| 2018 Q3 | 118.53 Million PLN | -33.45% |
| 2017 Q4 | 159.53 Million PLN | 0.41% |
| 2017 Q2 | 157.4 Million PLN | 2.58% |
| 2017 Q1 | 153.45 Million PLN | 9.1% |
| 2017 FY | 159.53 Million PLN | 13.42% |
| 2017 Q3 | 158.88 Million PLN | 0.93% |
| 2016 Q3 | 174.03 Million PLN | 9.18% |
| 2016 Q1 | 191.16 Million PLN | -1.33% |
| 2016 FY | 140.65 Million PLN | -27.4% |
| 2016 Q2 | 159.39 Million PLN | -16.62% |
| 2016 Q4 | 140.65 Million PLN | -19.18% |
| 2015 Q1 | 154.19 Million PLN | -7.57% |
| 2015 FY | 193.73 Million PLN | 16.14% |
| 2015 Q4 | 193.73 Million PLN | 10.49% |
| 2015 Q3 | 175.33 Million PLN | 6.72% |
| 2015 Q2 | 164.3 Million PLN | 6.55% |
| 2014 Q3 | 174.01 Million PLN | -0.4% |
| 2014 Q4 | 166.81 Million PLN | -4.13% |
| 2014 Q2 | 174.71 Million PLN | -11.01% |
| 2014 FY | 166.81 Million PLN | -15.98% |
| 2014 Q1 | 196.33 Million PLN | -1.11% |
| 2013 Q3 | 208.13 Million PLN | 5.0% |
| 2013 Q4 | 198.53 Million PLN | -4.61% |
| 2013 FY | 198.53 Million PLN | 7.61% |
| 2013 Q1 | 192.32 Million PLN | 4.24% |
| 2013 Q2 | 198.21 Million PLN | 3.06% |
| 2012 Q3 | 167.67 Million PLN | -21.59% |
| 2012 Q1 | 208.76 Million PLN | -12.73% |
| 2012 Q4 | 184.5 Million PLN | 10.03% |
| 2012 FY | 184.5 Million PLN | -22.88% |
| 2012 Q2 | 213.83 Million PLN | 2.43% |
| 2011 Q3 | 212.44 Million PLN | 27.18% |
| 2011 Q4 | 239.22 Million PLN | 12.61% |
| 2011 FY | 239.22 Million PLN | 94.18% |
| 2011 Q1 | 126.57 Million PLN | 2.74% |
| 2011 Q2 | 167.04 Million PLN | 31.97% |
| 2010 Q2 | 42.27 Million PLN | -67.23% |
| 2010 Q1 | 128.99 Million PLN | -34.58% |
| 2010 FY | 123.19 Million PLN | -37.52% |
| 2010 Q4 | 123.19 Million PLN | 29.81% |
| 2010 Q3 | 94.9 Million PLN | 124.51% |
| 2009 Q4 | 197.18 Million PLN | 0.0% |
| 2009 FY | 197.18 Million PLN | -54.25% |
| 2008 FY | 430.99 Million PLN | 18.78% |
| 2007 FY | 362.84 Million PLN | 7649.88% |
| 2006 FY | -4.8 Million PLN | -115.56% |
| 2005 FY | 30.88 Million PLN | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Bioceltix S.A. | -9.13 Million PLN | 809.452% |
| Captor Therapeutics Spolka Akcyjna | -71.92 Million PLN | 190.106% |
| Mabion S.A. | -11.98 Million PLN | 640.579% |
| Molecure S.A. | -56.84 Million PLN | 214.004% |
| NanoGroup S.A. | -537.61 Thousand PLN | 12155.162% |
| Pharmena S.A. | -22.05 Million PLN | 393.843% |
| Poltreg S.A. | -57.75 Million PLN | 212.212% |
| Pure Biologics Spólka Akcyjna | 9.33 Million PLN | -594.492% |
| Ryvu Therapeutics S.A. | -57.03 Million PLN | 213.636% |
| Synthaverse S.A. | 67.86 Million PLN | 4.506% |
| Urteste S.A. | -512 Thousand PLN | 12758.203% |